ADC Bio has commissioned a second dedicated R&D lab to meet customer demand for technical services to support ADCs in pre-clinical development. Surging interest in ADC anti-cancer drugs sees over 150 in pre-clinical development and nearly 50 in clinical trials.
Coming on stream earlier this year, emphasis in the latest £100,000 lab expansion is expanding service capabilities in payload-linker customisation and downstream bio-conjugation.
The company is one of just a handful of independent technical service providers in the fastest growing sector of oncology therapies.
ADC Bio now has three labs at St Asaph, with a total footprint of 210m and 12 science staff, including two additional chemistry staff focusing on payload-linker design. Overall this represents a 100% growth for the science teams in less than two years.
The third lab is dedicated to continuing development and commercialisation of the company’s core “Lock-Release” bio-conjugation technology that enables development of optimal ADC formats and expedites development of clinical ADC candidates.
The development mirrors continuing acceleration in the company’s technical services business and is the second significant increase in lab capabilities since 2012.
Previously, growing demand for its R&D services triggered a £125,000 lab expansion and matching staff additions in April 2013 – with further expansion in 2014.
ADC Bio has 10 worldwide repeat customers, won its 80th project during Q1 and was ahead-of-forecast for FY 2014/15, which ended in June.